Free trial

Ask AI to review this stock

Copy the prompt to get recent events, historical reactions, and a short research brief.

Tell your AI:

Help me set up FinLab and analyze 6782 視陽. Please read: https://finlab.finance/en/setup?stock=6782

No install, open FinLab Studio

6782

視陽 Biotech & Healthcare As of 2026-06-17 Updated daily after market close

strong quality, discounted valuation.

1 active signal

Revenue ≥20%

This page refreshes daily after the close. Add 視陽 to your watchlist to track signal changes on your next visit.

Is 視陽 a buy? Fundamentals and valuation first

Top-tier profitability.Operating margin beats ~91% of the market. Latest quarterly ROE ≈ 5.5%.
Valuation is low.PE is in the 17th market percentile; within its own history, PE is around the 1th percentile.
Foreign investors are net selling.Foreign 20-day net flow ≈ -2.3% of volume (net sell).
Strong revenue growth.Latest monthly revenue YoY ≈ 22.8%, above the 20% growth threshold.
Signals are active now.On the latest data, signals such as Revenue YoY ≥ 20% are active — see the historical forward returns after each occurrence below.

Chip flow

Bullish +0.43

BearishNeutralBullish

Single-sided accumulation, concentration rising — bullish

Single-sided accumulation, concentration rising — bullish
國票-台中 holds 389 lots
sellers have 186 lots left, ~147 sessions to clear

Window from 2026-01-17 · Price +7% · branches to 2026-06-17· TDCC to 2026-06-12

Largest holder 國票-台中 has accumulated 389 lots since the start (sold 8%), now trimming.
Main distributor 新加坡商瑞銀 peaked at 539 lots, has sold 54%, 249 left, paused recently.
TDCC big holders (absolute) >1000-lot holders +1.93pp, mid holders -2, retail +0.75pp — concentration shifting upward.
Foreign hedge-desk net short Net short -672 lots (inferred from branch profile, mostly hedging — not necessarily bearish, not case-confirmed).

Branch inventory reconstruction

Accumulating holders Branches that accumulated shares during the window and still hold positive inventory; they are the absorbing side.

Distributing sellers Branches that built inventory earlier and have been selling it down; the remaining number estimates what has not cleared.

Net-short desks Trading-desk branches with negative inventory or net selling, often hedge, offsetting, or short-term flow. It is not automatically a bearish view.

Accumulating

國票-台中華南永昌元大-台北兆豐-西螺中國信託玉山證券

Distributing

新加坡商瑞銀美林摩根大通永豐金-台中港商野村元大-莒光

Desks

own scale

台灣摩根士丹利凱基-桃園永豐金-桃園元大-龍潭

Price Accumulating & Distributing share one scale (comparable); Desks is independent. Zero is the baseline

Branch details Unit: lots

Accumulating

國票-台中 +389

sold 8%
華南永昌 +383

sold 0%
元大-台北 +310

sold 0%
兆豐-西螺 +197

sold 0%· still adding
中國信託 +125

sold 0%
玉山證券 +123

sold 4%· still adding

Distributing

新加坡商瑞銀 249 left

sold 54%· paused recently
美林 37 left

sold 88%· ~15 sessions to clear
摩根大通 44 left

sold 82%· ~147 sessions to clear
永豐金-台中 37 left

sold 79%· ~62 sessions to clear
港商野村 57 left

sold 53%· paused recently
元大-莒光 53 left

sold 47%· paused recently

Desks

台灣摩根士丹利 -425

hedge desk · will cover
凱基-桃園 -157

unclassified
永豐金-桃園 -147

unclassified
元大-龍潭 -129

unclassified

Still selling 186 lots ~147 sessions to bottom at most

Recent buy/sell force +258 absorbed / -100 sold buyers slightly ahead

Hedge-desk net short -494 lots potential cover-buying, not selling pressure

TDCC big holders · absolute-holding cross-check

>1000-lot holder share Retail (<400 lots) share Price (right axis)

Mixed direction: big-holder and retail changes are not aligned.

Describes chip flow, not investment advice. Branch data discloses only high-volume branches with ~1-day lag; TDCC is weekly. Inventory is a relative reconstruction from the window start, not absolute holdings.

Historical evidence

Signals active now

These signals are true on the latest data, with this stock's own historical forward-return stats after each occurrence.

Monthly revenue YoY ≥ 20% (from filing deadline)

Active · now 22.78%

Monthly revenue YoY ≥ 20%; event date is the first trading day after the filing deadline (no look-ahead).

21 historical occurrences (since 2022-11-28)

120 days after: historical avg -6.01%

20-day +0.19%

60-day +2.58%

120-day -6.01%

20-day

60-day

120-day

Win

50%

47.4%

29.4%

Sample

Median

-0.11%

-0.68%

-9.92%

Excess

-3.67%

-7.22%

-22.05%

Beat mkt rate

30%

26.3%

11.8%

Over 17 occurrences, 120-day forward avg declined 6.01%, lagged the market by 22.05 pts; win rate 29.4%.

Valuation regime and subsequent returns

Each day's PE is converted to its own-history percentile (as of that day), then we look at adjusted-close returns over the next 240 trading days by valuation regime.

0-20 Insufficient data Now

20-40 Insufficient data

40-60 Insufficient data

60-80 Insufficient data

80-100 Insufficient data

PE percentile band	Sample days	240-day avg return	Median	Win rate	Avg excess (vs index)
0-20 You are here	0	Insufficient data
20-40	0	Insufficient data
40-60	0	Insufficient data
60-80	0	Insufficient data
80-100	0	Insufficient data

Percentiles use an expanding own-history window (no look-ahead); forward return is 240 trading days on adjusted close. Sample days overlap; distribution is indicative only.

Current PE ≈ 12.85, at the 0.9th percentile of its own history (0-20 band).

Valuation × momentum historical grid

Every day in its own history is bucketed by valuation tercile (own-history PE) and 60-day momentum sign into six cells; we show adjusted-close returns over the next 120 trading days per cell.

Valuation

Momentum

Cheap (own-history bottom 1/3)

Mid

Expensive (own-history top 1/3)

60-day momentum up

Insufficient data
(0d)

60-day momentum down

Now

Insufficient data
(0d)

Days = trading days in this bucket; returns use adjusted prices, ex-costs. 60-day momentum: direction of this stock's price over the past 60 trading days.

Does this signal hold up across the market

Over the past 242 months, on average ~404 stocks per month met “monthly revenue YoY ≥ 20%”; their adjusted-close return over the next 60 trading days averaged 6.94% (equal-weighted), beating the market by 2.37 points on average, and outperformed the TAIEX total-return index in 64.5% of months.

Each month, equal-weighted 60-day forward adjusted return of all signal-matching stocks, then averaged across months; excess vs the TAIEX total-return index.

Signals not active (historical stats for reference)

These are not occurring now; historical samples shown for comparison.

252-day price high (breakout)

Pending

Adjusted close makes a new 252-day high; repeats within 20 days counted once.

Foreign net buying for 5 straight days

Pending

Foreign net flow (ex-dealer) positive for 5 straight days; event on day 5; repeats within 20 days counted once.

11 times historically; 60-day forward avg -0.68%, win rate 63.6%, beating the market by -15.06 pts on average.

What does 視陽 do? Company profile

生技醫療業上市（臺灣證券交易所）

Overview

視陽光學股份有限公司成立於1998年11月9日，股票代號6782，為臺灣證券交易所上市普通股，2020年公開發行並登錄興櫃，2022年11月28日上市。總部位於桃園市龜山區興業街1號，另揭露桃園市桃園區幸福路200號7樓；主要製造基地位於馬來西亞檳城。董事長與總經理皆為李重儀，發言人為副總經理吳滄松，代理發言人為財會處長鄭佩青。2025年年報揭露實收資本額為新台幣6.30億元、發行股數63,000,000股；2025年底員工1,613人，2026年2月28日為1,608人，其中研發人員79人。主要股東截至2026年3月28日包含明基材料股份有限公司14.82%、狄安邁國際有限公司5.21%、李焜耀4.99%、黃湘雅2.33%、黃廷佐2.20%、上東投資有限公司2.04%、李麗芳1.64%、匯豐受託保管摩根士丹利國際投資專戶1.44%、游志宇1.30%、林碧珠1.27%。關係企業包含馬來西亞Visco Technology Sdn. Bhd.（隱形眼鏡製造加工及銷售）、Visco Med Sdn. Bhd.（租賃及管理服務）、日本From-eyes Co., Ltd.（隱形眼鏡銷售）、川揚商貿（上海）有限公司（隱形眼鏡銷售）及川揚視康股份有限公司（醫務管理顧問服務）。公司自稱為亞洲第一、全球第五的矽水膠隱形眼鏡製造商，並取得ISO 13485、日本FMR/FMA、MDSAP及美國QSR等品質系統或市場相關認證，產品證照涵蓋歐洲、美國、加拿大、臺灣、日本、中國大陸、韓國、澳洲、紐西蘭等市場。

Business

公司主要經營拋棄式軟性隱形眼鏡之生產、設計與銷售，2025年營收新台幣42.232億元，其中隱形眼鏡收入42.211億元、占99.95%，其他收入0.05%。產品依使用週期分為日拋、雙週拋、月拋；依功能分為近視/遠視矯正、散光、多焦/老花、抗藍光、彩妝與定位型彩妝鏡片。核心定位為矽水膠隱形眼鏡ODM/OEM及部分自有品牌/通路經營，矽水膠產品訴求高透氧、低彈性模數與舒適度，並以全球主要市場證照、產品設計、材料與自動化製程作為進入障礙。2025年銷售區域為內銷新台幣4.4716億元、占10.59%；外銷新台幣37.7604億元、占89.41%，其中亞洲28.4191億元、占67.29%，歐洲7.156億元、占16.94%，美洲2.1853億元、占5.18%。2026年第一季法說會揭露單季營收新台幣12.29億元，亞洲占79%、歐洲14%、美洲7%。商業模式以服務全球區域大型通路商、隱形眼鏡品牌商及自有品牌客戶為主，提供鏡片設計、製造、證照與客製化產品。年報揭露2025年主要客戶代號C占銷貨15.43%，明基材料占10.25%，單一客戶未超過20%。公司在日本、中國市場經營自有品牌refrear，並導入臺灣市場；日本市場另透過From-eyes貼近品牌、通路與終端需求。主要製程包括射出、移印（彩片）、注膠、固化、脫模、水化、檢驗、封包、滅菌與包裝。主要原料包含HEMA、矽氧烷壓克力、聚丙烯塑膠料、鋁箔及包材等。

Outlook 2025–2028

2025年公司營收及獲利創高，營收42.2億元、年增15%，毛利率45%，每股盈餘14.08元；成長來自新客戶、新產品、矽水膠產品線拓展、良率與效率改善，以及日本矽水膠散光、散光彩色與定位型彩色鏡片拉貨。2025年上半年平均產能利用率已提升至95%以上，第四季月產能達4,900萬片。2026年公司展望指出，在關稅措施趨穩、歐美降息環境帶動消費力回升、日本新客戶與新產品需求強勁、中國市場回溫下，預期營收與獲利持續成長；歐美市場將推進老花與散光矽水膠隱形眼鏡，亞太市場加大定位型矽水膠彩色隱形眼鏡及抗藍光產品。中長期到2027至2028年，合理成長動能來自全球矽水膠滲透率提升、日拋/短週期化、高階功能鏡片如散光與多焦需求、亞洲彩片與健康訴求結合、歐美通路自有品牌尋求四大品牌以外的高規格供應商、全球證照與馬來西亞產能/關稅優勢。公司年報列示的研發方向包含改良老花與散光光學設計、矽水膠抗藍光、保濕配方與表面處理、不同含水與透氧矽水膠材料、抗疲勞鏡片、近視控制產品、AI檢測、彩片印刷自動調整、生產自動化與表面處理製程降本。主要風險包括美國關稅變化、日幣低迷與馬幣升值造成匯率壓力、原物料與通膨、四大國際品牌寡占與價格競爭、後進者推出矽水膠產品、中國本土製造能力提升、各國醫療器材證照法規趨嚴、客戶新品導入與取證時程不確定、產能利用率高時的擴產執行與良率風險。2027至2028並無公司逐年量化財測，本段為依公司年報、法說會與產業趨勢的研究推估。

Supply Chain

Upstream

明基材料股份有限公司 8215 年報揭露為2025年主要供應商，進貨金額新台幣2.08717億元、占全年進貨20.01%，並標示為本公司之其他關係人；明基材料亦為臺灣上市公司。
HEMA、矽氧烷壓克力、聚丙烯塑膠料、鋁箔及包材供應商年報揭露主要原料類別及供應狀況良好，但除明基材料外未揭露其他具名供應商；多數供應商身分未公開，無法確認是否上市櫃。
自動化設備、模具、檢測與包裝設備供應商公司持續導入自動化、AI檢測、彩片印刷自動調整與產線監控系統，惟年報未揭露具名設備供應商。

Downstream

客戶C 年報以代號揭露之最大銷貨客戶，2025年銷貨新台幣6.51723億元、占15.43%；名稱未公開，無法確認掛牌狀態。
明基材料股份有限公司 8215 年報揭露為2025年主要銷貨客戶之一，銷貨新台幣4.33002億元、占10.25%，並標示為本公司之其他關係人。
歐洲、美洲、亞洲大型通路商與隱形眼鏡品牌商公司銷售客戶以各區域大型通路商或品牌商為主，部分經營自有品牌，年報未揭露多數客戶名稱；屬下游品牌、電商、眼鏡店、眼科診所與專業視光通路。
From-eyes Co., Ltd. 視陽日本子公司，負責隱形眼鏡銷售與日本在地品牌/通路服務；非台股掛牌公司。
川揚商貿（上海）有限公司視陽中國大陸子公司，負責隱形眼鏡銷售；非台股掛牌公司。

Competitors

晶碩光學股份有限公司 6491 臺灣上市隱形眼鏡廠，從事拋棄式軟性隱形眼鏡研發、製造、銷售與自有品牌PEGAVISION，為臺灣隱形眼鏡同業主要競爭者。
精華光學股份有限公司 1565 臺灣上櫃隱形眼鏡廠，具代工與自有品牌帝康/Ticon，為臺灣隱形眼鏡同業競爭者。
望隼科技股份有限公司 4771 臺灣上市隱形眼鏡製造商，市場資料常與視陽、晶碩、精華並列為台灣隱形眼鏡族群。
金可-KY 8406 臺灣上市公司，主要品牌包含海昌等，在中國與亞洲隱形眼鏡市場具品牌與通路競爭關係。
明基材料股份有限公司 8215 臺灣上市材料與醫材公司，除為視陽主要供應商及關係人，也布局隱形眼鏡醫材產品，具上下游及部分競合關係。
Johnson & Johnson Vision / Acuvue 國際四大隱形眼鏡品牌之一；母公司Johnson & Johnson為美國上市公司，非台股掛牌。
Alcon 國際四大隱形眼鏡品牌之一，產品包含Dailies、Total等；瑞士/美國上市公司，非台股掛牌。
CooperVision 國際四大隱形眼鏡品牌之一，母公司The Cooper Companies為美國上市公司，非台股掛牌。
Bausch + Lomb 國際四大隱形眼鏡與眼科產品公司之一，美國/加拿大上市公司，非台股掛牌。
Menicon 日本隱形眼鏡品牌與製造商，在日本及全球市場具競爭關係；非台股掛牌。

Sources（16）

This company profile is compiled from public sources (annual reports, filings, news and analyst reports), not finlab backtest data; the 2025–2028 outlook contains forward-looking estimates and is for reference only.

Method and limitations

All returns use adjusted close (etl:adj_close), already adjusted for dividends and splits.
Excess return is measured against the TAIEX total-return index (dividends included).
Valuation regime and percentile stats use an expanding own-history window (no future data).
Revenue-signal event dates align to the first trading day after the filing deadline, avoiding look-ahead.
Event samples may overlap in time; stats describe historical distribution only and are less reliable when samples are few.

This page is historical statistics for educational purposes and is not investment advice. Investing involves risk; past performance does not indicate future results. Assess and bear the risk yourself before trading.